Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome

Journal of Clinical Rheumatology

Volumn 21, Issue 6, 2015, Pages 311-313

  Zikos, Thomas A ^a   Sokolove, Jeremy ^a   Ahuja, Neera ^a   Berube, Caroline ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiphospholipid syndrome; Catastrophic antiphospholipid syndrome; Complement cascade; Eculizumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARDIOLIPIN ANTIBODY; CREATININE; ECULIZUMAB; FIDAXOMICIN; FRESH FROZEN PLASMA; HEPARIN; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE; LEVOFLOXACIN; LUPUS ANTICOAGULANT; MENINGOCOCCUS VACCINE; METRONIDAZOLE; PREDNISONE; VANCOMYCIN; VITAMIN K GROUP; WARFARIN; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD SMEAR; CASE REPORT; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; CHEMOSIS; CHOLECYSTECTOMY; CHOLELITHIASIS; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIALYSIS; DIARRHEA; FEVER; HEPATOSPLENOMEGALY; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOXEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL NORMALIZED RATIO; KIDNEY INFARCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG THROMBOSIS; LEUKOCYTOSIS; LIVER DISEASE; LIVER FUNCTION TEST; LIVER INFARCTION; LOWER EXTREMITY DEEP VEIN THROMBOSIS; MALE; MEDICAL HISTORY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN THERAPY; PATIENT TRANSPORT; PEPTOCLOSTRIDIUM DIFFICILE; PERICARDIAL EFFUSION; PLASMAPHERESIS; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REMISSION; RESPIRATORY FAILURE; RESPIRATORY TRACT INTUBATION; SPLENOMEGALY; THROMBOCYTE COUNT; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; VISUAL IMPAIRMENT; ADVERSE EFFECTS; DRUG MONITORING; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; PROCEDURES; RECURRENT DISEASE; TERMINAL DISEASE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIPHOSPHOLIPID SYNDROME; CATASTROPHIC ILLNESS; CHOLECYSTECTOMY; COMPLEMENT INACTIVATING AGENTS; DRUG MONITORING; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; TREATMENT OUTCOME;

EID: 84940905884     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000290     Document Type: Article

References (13)

1. Cervera R, Piette JC, Font J, Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002; 46: 1019-1027.
2. Cervera R, Bucciarelli S, Plasín MA, Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun. 2009; 32: 240-245.
3. Cervera R, Espinosa G,. Update on the catastrophic antiphospholipid syndrome and the "CAPS Registry". Semin Thromb Hemost. 2012; 38: 333-338.
4. Berman H, Rodríguez-Pintó I, Cervera R, Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013; 12: 1085-1090.
5. Girardi G, Redecha P, Salmon JE,. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004; 10: 1222-1226.
6. Zuber J, Fakhouri F, Roumenina LT, Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012; 8: 643-657.
7. Shapira I, Andrade D, Allen SL, Brief report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum. 2012; 64: 2719-2723.
8. Kronbichler A, Frank R, Kirschfink M, Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: A case report. Medicine (Baltimore). 2014; 93: E143.
9. Strakhan M, Hurtado-Sbordoni M, Galeas N, 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: A case report and review of literature. Case Rep Hematol. 2014; 2014: 704371.
10. Lonze BE, Zachary AA, Magro CM, Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. 2014; 14: 459-465.
11. Canaud G, Kamar N, Anglicheau D, Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant. 2013; 13: 2179-2185.
12. Lonze BE, Singer AL, Montgomery RA,. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010; 362: 1744-1745.
13. Agostinis C, Durigutto P, Sblattero D, A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood. 2014; 123: 3478-3487.